Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting 2025 (GlobeNewswire) - Nov 10, 2025 - "In this qF4 subgroup, denifanstat treatment improved fibrosis by 1-2 qFibrosis stages with a response rate for ≥1 qFibrosis stage regression of 85% (11/13) for denifanstat vs. 33% (1/3) in placebo-treated patients...Additional findings: In F3 MASH patients, using clinical research network (CRN) scoring, the response rate for fibrosis improvement by ≥2 stages without worsening of MASH was 34% (16/47) for denifanstat, vs. 4% (1/23) in placebo-treated patients (p value = 0.0065); In qF4 MASH patients, using MASH CRN scoring, the response rate for fibrosis improvement by ≥1 stage was 39% (5/13) for denifanstat, of which 4/5 patients had 2 stages of improvement, vs. 0% (0/3) in placebo-treated patients...The second poster...Quantitative single-fiber traits and clustering revealed fibrosis phenotypes that predicted denifanstat response, supporting that computational pathology could be leveraged for response stratification."
P2b data • Metabolic Dysfunction-Associated Steatohepatitis
|